Literature DB >> 16740632

Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling.

Serena Germano1, Davide Barberis, Massimo M Santoro, Lorenza Penengo, Ami Citri, Yosef Yarden, Giovanni Gaudino.   

Abstract

Ron, the tyrosine kinase receptor for macrophage-stimulating protein is responsible for proliferation and migration of cells from different tissues. Ron can acquire oncogenic potential by single point mutations in the kinase domain, and dysregulated Ron signaling has been involved in the development of different human cancers. We have previously shown that ligand-activated Ron recruits the negative regulator c-Cbl, which mediates its ubiquitylation and degradation. Here we report that Ron is ubiquitylated also by the U-box E3 ligase C-terminal Hsc70-interacting protein (CHIP), recruited via chaperone intermediates Hsp90 and Hsc70. Gene silencing shows that CHIP activity is necessary to mediate Ron degradation upon cell treatment with Hsp90 inhibitors geldanamycins. The oncogenic Ron(M1254T) receptor escapes from c-Cbl negative regulation but retains a strong association with CHIP. This constitutively active mutant of Ron displays increased sensitivity to geldanamycins, enhanced physical interaction with Hsp90, and more rapid degradation rate. Cell growth and migration, as well as the transforming potential evoked by Ron(M1254T), are abrogated upon Hsp90 inhibition. These data highlight a novel mechanism for Ron degradation and propose Hsp90 antagonists like geldanamycins as suitable pharmacological agents for therapy of cancers where altered Ron signaling is involved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740632     DOI: 10.1074/jbc.M602014200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

Review 2.  Degradation of activated protein kinases by ubiquitination.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

3.  Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.

Authors:  Melanie B Laederich; Catherine R Degnin; Gregory P Lunstrum; Paul Holden; William A Horton
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

Review 4.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

Review 5.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 6.  Ron-receptor tyrosine kinase in tumorigenesis and metastasis.

Authors:  Mike A Leonis; Megan N Thobe; Susan E Waltz
Journal:  Future Oncol       Date:  2007-08       Impact factor: 3.404

7.  Heat shock factor 1 deficiency via its downstream target gene alphaB-crystallin (Hspb5) impairs p53 degradation.

Authors:  Xiongjie Jin; Demetrius Moskophidis; Yanzhong Hu; Andrew Phillips; Nahid F Mivechi
Journal:  J Cell Biochem       Date:  2009-06-01       Impact factor: 4.429

Review 8.  The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Authors:  Chang Moo Kang; Michele L Babicky; Andrew M Lowy
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

9.  Ecology-based screen identifies new metabolites from a Cordyceps-colonizing fungus as cancer cell proliferation inhibitors and apoptosis inducers.

Authors:  Y Chen; H Guo; Z Du; X-Z Liu; Y Che; X Ye
Journal:  Cell Prolif       Date:  2009-08-11       Impact factor: 6.831

10.  Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells.

Authors:  Shujie Zhao; Sudhakar Ammanamanchi; Michael Brattain; Lin Cao; Amalraj Thangasamy; Jing Wang; James W Freeman
Journal:  J Biol Chem       Date:  2008-02-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.